The International Council for Harmonisation (ICH) updated the validation guideline ICH Q2(R2) alongside ICH Q14 on Analytical Procedure Development. This marks the most significant evolution in analytical validation frameworks in nearly three decades.
Key Changes Introduced in ICH Q2(R2)
Unlike its predecessor ICH Q2(R1), the revision incorporates spectroscopic methods (NIR, Raman, NMR), high-resolution chromatographic techniques, and multivariate analytical procedures. It emphasizes life-cycle management and risk-based validation protocols.
Core Validation Parameters Under ICH Q2(R2):
- Specificity & Selectivity: Demonstrating unequivocal assessment of the target analyte in the presence of degradants, excipients, and impurities.
- Linearity & Range: Establishing mathematical models (linear or non-linear) over the working operational range.
- Accuracy / Recovery: Closeness of agreement between the accepted reference value and the experimental value.
- Repeatability & Intermediate Precision: Within-laboratory variations across analysts, instruments, and days.
- Robustness & Sensitivity: Evaluation of deliberate variations in method conditions such as flow rate, column temperature, and mobile phase pH.
Why Life-Cycle Validation Matters for Regulatory Filings
Regulatory agencies such as the US FDA, EMA, and WHO expect analytical procedures to be grounded in Quality by Design (QbD) principles. At KemQuest Pharma Services, our lead analytical scientists develop and validate analytical methods strictly conforming to current ICH Q2 guidelines, providing audit-ready reports and protocol execution for global dossier submissions.
Conclusion
Adopting ICH Q2(R2) early reduces the risk of deficiency letters, simplifies post-approval lifecycle variations, and ensures patient safety through reliable, reproducible analytical results.